High CCNB2 expression correlates with poor prognosis in hepatocellular carcinoma
  
View Full Text  View/Add Comment  Download reader
DOI:10.46701/APJBG.2019012019110
KeyWord:CCNB2, hepatocellular carcinoma, tissue microarray, immunohistochemistry, prognosis
                 
AuthorInstitution
Xiaolu Zhai Department of Oncology, the Second Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001 China
Yingjing Wang Department of Pathology, Medical School of Nantong University, Nantong, Jiangsu, 226001 China
Pei Chen Department of Oncology, Medical School of Nantong University, Nantong, Jiangsu, 226001 China
Mengjing Sun2, Department of Pathology, Medical School of Nantong University, Nantong, Jiangsu, 226001 China
Jianwei Qiu Department of Gastroenterology, the Second Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001 China
Yao Wang Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu, 226001 China
Hits: 1805
Download times: 2394
Abstract:
      Cyclin B2 (CCNB2), a member of the cyclin protein family, has a key role in the progression of G2/M transition. However, the clinical value of CCNB2 in hepatocellular carcinoma (HCC) is still unknown. The aim of our study is to identify the role of CCNB2 in HCC patients. Immunohistochemical analysis using tissue microarray (TMA) was employed to evaluate the expression of CCNB2 in HCC and the correlation between CCNB2 expression and clinicopathological features in HCC patients. The relationship between CCNB2 expression and the prognosis of HCC patients was analyzed using Oncomine and Kaplan-Meier Plotter online resources. High CCNB2 cytoplasmic expression was observed in 77.22% of patients with HCC, which was related to differentiation (P<0.001), tumor diameter (P=0.025), and hepatitis B virus infection (P=0.008). High CCNB2 nuclear expression was seen among 43.43% of cases, which was associated with differentiation (P=0.001). CCNB2 levels were inversely proportional to patient prognosis. The study suggests that CCNB2 expression could be an effective prognostic biomarker for HCC.
Close